Summary of Mindray (300760.SZ) Earnings Review Company Overview - **Company**: Mindray (300760.SZ) - **Industry**: Medical Technology (Medtech) Device Manufacturing Key Financial Results - **FY25 Revenue**: Rmb33,282 million, a decrease of 9% year-over-year (yoy), in line with Goldman Sachs estimates (GSe) of Rmb33,442 million [1] - **Net Profit**: Rmb8,136 million, down 30% yoy, missing GSe of Rmb8,771 million [1] - **Gross Profit Margin**: Lower than expected due to VBP pricing erosion, higher R&D expenses, and exchange losses [1] Revenue Breakdown - **Core Business Revenue Declines**: - Patient Monitoring and Life Support (PMLS): -20% yoy - Medical Imaging: -18% yoy - In Vitro Diagnostics (IVD): -9% yoy [1] - **Emerging Businesses**: Recorded 39% yoy growth, including APT Medical, animal healthcare, and surgery [1] - **Overseas Business**: Grew by 7% yoy, now accounting for 53% of total revenue [2] - **Domestic Business**: Declined by 23% yoy due to: - Price reductions from Volume-Based Procurement (VBP) - Decreased usage of IVD reagents due to DRG/DIP reforms - Channel destocking of PMLS & Medical Imaging devices [2] Future Outlook - **2026 Revenue Expectations**: Anticipated to turn positive, driven by Emerging Businesses growth [6] - **Overseas Growth**: Expected to outpace domestic growth, with all three core businesses projected to see some growth [6] - **Impact of Middle East Crisis**: Minimal effect on raw material supply; however, sales to the region have been significantly impacted, accounting for a single-digit percentage of overseas revenue [6] - **R&D Investment**: Expected to increase in 2026, with potential exchange rate losses due to RMB appreciation [6] Revised Estimates - **2026E Revenue**: Rmb36,067 million, a decrease of 2.4% from previous estimates [7] - **2026E Net Profit**: Rmb8,306 million, down 18.6% from prior estimates [7] - **EPS**: Expected to be Rmb6.85 for 2026, a reduction of 18.6% from previous forecasts [7] Investment Thesis - **Market Position**: Mindray is a leading medtech device manufacturer in China, with strong growth potential due to healthcare infrastructure development and domestic substitution [9] - **Valuation**: Currently trading below its 5-year average forward P/E, primarily due to policy risks [9] - **Key Catalysts**: Recovery in procurement activities, updates on medical device trade-in programs, and new product launches [9] Price Target and Risks - **12-Month Price Target**: Rmb247, representing a 44.6% upside from the current price of Rmb170.77 [11] - **Key Risks**: - Further impacts from VBP on product pricing - Slower-than-expected penetration into top-tier hospitals in China - Challenges in entering North American and European markets - Patent-related lawsuit risks - Unexpected changes in trade policies [10] Conclusion - Mindray's performance in FY25 reflects significant challenges, particularly in domestic markets, but the company is positioned for potential recovery and growth through its emerging business segments and overseas expansion. The revised estimates indicate a cautious outlook, with a maintained Buy rating based on long-term growth potential and market leadership.

Summary of Shenzhen Mindray FY25 Earnings Call Company Overview - **Company**: Shenzhen Mindray (300760.SZ) - **Industry**: Medical Devices and Equipment Financial Performance - **Revenue**: Rmb33.3 billion, a decrease of 9.4% year-over-year (YoY) [1] - **Net Profit**: Rmb8.1 billion, down 30.3% YoY, or 29.5% YoY excluding one-off items [1] - **Gross Margin (GM)**: Decreased to 60.3% in FY25 from 63.1% in FY24 [1] - **Operating Profit Margin (OPM)**: Decreased to 28.3% from 33.3% [1] - **Selling Expense Ratio**: Increased to 15.5% from 14.4% [1] - **R&D Expense Ratio**: Increased to 10.8% from 10% [1] - **Net Margin**: Decreased to 24.4% from 31.8% [1] Dividend Information - **Final Dividend**: Rmb376 million (tax-inclusive) [1] - **Total Cash Dividend for FY25**: Rmb5.31 billion (tax-inclusive), representing a dividend payout ratio of 65.27% [1] Valuation - **Target Price**: Rmb285, based on a Discounted Cash Flow (DCF) and Sum of the Parts (SOTP) model [5] - **Valuation Breakdown**: - PMLS: Rmb68 - IVD: Rmb140 - Medical Imaging: Rmb41 - Electrophysiology and Vascular Intervention Products: Rmb9 - Net Cash: Rmb17 - Others: Rmb12 - **Weighted Average Cost of Capital (WACC)**: 9.2% [5] - **Terminal Growth Rate**: 3% [5] Market Outlook - **Current Share Price**: Rmb170.770 [3] - **Expected Share Price Increase**: 66.9% [3] - **Expected Dividend Yield**: 3.3% [3] - **Expected Total Return**: 70.2% [3] - **Market Capitalization**: Rmb207,049 million (approximately US$29,956 million) [3] Risks - **Geopolitical Risks**: U.S.-China trade tensions could impact revenue sources and global raw material sourcing [6] - **GPO Impact**: Potential adverse effects if product prices are significantly reduced and volume increases cannot offset price drops [6] - **Patent Protection**: Risks associated with obtaining patent protection due to varying regulatory requirements [6] - **Market Demand**: Failure to accurately assess technological trends and customer needs could adversely affect financial conditions [6] - **Supply Chain Interruptions**: Delays in material or component supplies could negatively impact manufacturing processes [6] - **Distribution Network Disruptions**: Any disruptions could affect the ability to effectively sell products [6] Conclusion Shenzhen Mindray's FY25 results indicate significant challenges with declining revenues and profits, alongside increased expenses. The company maintains a strong dividend payout and has a positive outlook based on its target price and expected returns, but faces several risks that could impact future performance.

Summary of Key Points from the Conference Call Company Overview - **Company**: Mindray Medical International Limited - **Industry**: Medical Devices Financial Performance - **2025 Revenue**: 332.7 billion RMB, a decrease of 18.4% year-on-year [2] - **Net Profit**: 81.35 billion RMB, down 38.54% year-on-year [2] - **Q4 Performance**: Revenue of 74.48 billion RMB, a 2.86% increase year-on-year; net profit of 6.38 billion RMB, down 38.54% year-on-year [4] - **Cash Flow**: Operating cash flow net amount of 101.45 billion RMB, down 18.4% year-on-year [4] Business Segments International Business - **Revenue**: 176.5 billion RMB, accounting for 53% of total revenue, with a growth of 7.4% year-on-year [2] - **European Market Growth**: 17% increase, with emerging business segments growing nearly 30% [5] - **Future Outlook**: Expected rapid growth in international business in 2026, driven by localization and high-end customer penetration [5] Domestic Business - **Revenue**: 156.32 billion RMB, down 22.97% year-on-year [2] - **IVD Business**: Accounts for nearly 50% of domestic revenue; aims to double market share in immunology, biochemistry, and coagulation within three years [2][5] - **Emerging Business**: Revenue of 53.78 billion RMB, up 38.85%, representing 16% of total revenue; identified as a key growth driver [2][8] Research and Development - **R&D Investment**: 39.29 billion RMB, 11.8% of revenue [9] - **New Products**: Launch of various diagnostic kits and automated systems across multiple medical fields [9] Shareholder Returns - **Dividends**: 53.1 billion RMB in total dividends for 2025, representing 65.27% of net profit [3][4] Strategic Initiatives - **Hong Kong IPO**: Planned to deepen international presence and enhance brand recognition [11][12] - **Collaboration with Medtronic**: Strengthening partnerships with international giants to enhance technology and market reach [13][14] Market Challenges and Opportunities - **Domestic Market**: Facing challenges due to budget cuts in hospital procurement and policy impacts on IVD business [5][19] - **International Market**: Slower growth in 2025 due to macroeconomic factors; however, potential for recovery in 2026, especially in Europe [22][23] Sustainability and Corporate Responsibility - **Sustainability Report**: Released eighth report, maintaining AA rating from MSCI ESG [10] - **Social Initiatives**: Ongoing projects to enhance healthcare access and training [10] Future Outlook - **Growth Strategy**: Focus on IVD business and emerging sectors to drive future growth; aiming for a return to rapid growth by 2027 [24] - **Market Positioning**: Targeting to enter the top ten global medical device companies within ten years [12] Conclusion - **Overall Assessment**: Despite facing significant challenges in both domestic and international markets, the company is strategically positioned for future growth through innovation, international expansion, and a focus on emerging business segments.

Investment Rating - The investment rating for the company is "Buy" [2][6] Core Views - The company's performance is under short-term pressure, but emerging businesses are showing strong growth potential. The company achieved a revenue of 33.282 billion RMB in 2025, a year-on-year decline of 9.38%, and a net profit of 8.136 billion RMB, down 30.28% year-on-year. However, the fourth quarter of 2025 saw a revenue increase of 2.86% year-on-year, indicating signs of recovery [4][6]. - The international business is steadily progressing, with international revenue reaching 17.650 billion RMB, a year-on-year increase of 7.40%, accounting for 53% of total revenue. The domestic business is stabilizing, and new businesses are rapidly developing, which, combined with digitalization, is expected to lead to a quick recovery in performance [9] Summary by Sections Financial Performance - In 2025, the company reported total revenue of 33.282 billion RMB, with a net profit of 8.136 billion RMB. The projected net profits for 2026-2028 are 9.450 billion RMB, 11.307 billion RMB, and 13.045 billion RMB, respectively [6][11]. - The earnings per share (EPS) for 2026 is projected to be 7.79 RMB, with a price-to-earnings (P/E) ratio of 21.1 [6][11]. Business Segments - The in-vitro diagnostics (IVD) business generated 12.241 billion RMB in revenue, down 9.41% year-on-year, while the life information and support business reported 9.837 billion RMB, down 19.80% year-on-year. The emerging business segment, including minimally invasive surgery and animal healthcare, achieved 5.378 billion RMB, a year-on-year increase of 38.85% [9][10]. - The company is focusing on high-end strategic customer penetration and local platform construction, particularly in the European market, which is expected to continue its growth trajectory [9]. Market Outlook - The IVD industry is entering a period of adjustment due to multiple policy impacts, while the equipment sector is in a weak recovery phase. The company is expected to benefit from the recovery of domestic business and the continued expansion of international operations [6][9]. - The projected revenue growth rates for 2026-2028 are 4.3%, 17.6%, and 16.5%, respectively, indicating a positive outlook for the company's future performance [11].

Investment Rating - The investment rating for the company is "Buy" [2][6] Core Views - The company's performance is under short-term pressure, but emerging businesses are showing strong growth potential. The company achieved a revenue of 33.282 billion RMB in 2025, a year-on-year decline of 9.38%, and a net profit of 8.136 billion RMB, down 30.28% year-on-year. However, the fourth quarter of 2025 saw a revenue increase of 2.86% year-on-year, indicating signs of recovery [4][6]. - The international business is steadily progressing, with international revenue reaching 17.650 billion RMB, a year-on-year increase of 7.40%, accounting for 53% of total revenue. The domestic business is stabilizing, and new businesses are rapidly developing, which, combined with digitalization, is expected to lead to a quick recovery in performance [9] Summary by Sections Financial Performance - In 2025, the company reported total revenue of 33.282 billion RMB, with a net profit of 8.136 billion RMB. The projected net profits for 2026-2028 are 9.450 billion RMB, 11.307 billion RMB, and 13.045 billion RMB respectively, with corresponding EPS of 7.79 RMB, 9.33 RMB, and 10.76 RMB [6][8][11]. - The EBITDA for 2026 is estimated at 11.662 billion RMB, with a PE ratio of 21.1 for 2026, decreasing to 15.3 by 2028 [8][11]. Business Segments - The in-vitro diagnostics (IVD) business generated 12.241 billion RMB in revenue, down 9.41% year-on-year, while the life information and support business reported 9.837 billion RMB, down 19.80% year-on-year. The emerging business segment, including minimally invasive surgery and animal healthcare, achieved 5.378 billion RMB, growing 38.85% year-on-year [9][10]. - The company is focusing on high-end strategic customer penetration and local platform construction, with significant growth in the European market expected to continue [9]. Market Position - The company’s market share in core IVD businesses is around 10%, indicating substantial room for growth. The international market share for the life information and support business is increasing, with expectations for stable and rapid growth in the future [9][10].

Core Viewpoint - The company reported a decline in revenue and net profit for 2025, while focusing on product iteration and the construction of a "device + IT + AI" smart medical ecosystem [2][3][25]. Performance Summary - In 2025, the company achieved operating revenue of 33.282 billion yuan, a year-on-year decrease of 9.38% - The net profit attributable to shareholders was 8.136 billion yuan, down 30.28% year-on-year [3]. - The non-recurring net profit was 8.069 billion yuan, a decline of 29.48% year-on-year - Operating cash flow was 10.145 billion yuan, down 18.40% year-on-year - The weighted ROE was 21.58%, a decrease of 11 percentage points - Total assets reached 59.267 billion yuan, an increase of 4.63% year-on-year - Net assets attributable to shareholders were 38.093 billion yuan, up 6.24% year-on-year [5]. Revenue Structure - International business revenue was 17.650 billion yuan, an increase of 7.40% year-on-year, accounting for 53% of total revenue - Domestic business revenue was 15.632 billion yuan, a decrease of 22.97% year-on-year [5]. Product and Technology - The company is advancing product upgrades in the in vitro diagnostics (IVD) sector, focusing on full laboratory solutions [7]. - The MT 8000 full laboratory intelligent assembly line was installed in over 20 overseas locations and received more than 360 new orders domestically [8]. - The company introduced 14 new immunoassay reagents, bringing the total to 94, with some achieving "mass spectrometry level" performance [10]. - The company is developing a monitoring and anesthesia integration system for surgical and ICU scenarios [11]. - The Resona A20 high-end ultrasound system is designed for tumor and complex disease imaging, featuring microvascular perfusion imaging capabilities [14]. R&D, Business, and Market - The company continues to invest in R&D, global expansion, and the construction of a smart medical ecosystem [21]. - Over 21,000 employees globally, with more than 24% in R&D roles, and multiple R&D centers established worldwide [23]. - The IVD business accounts for approximately 48% of domestic revenue, with emerging businesses and IVD combined accounting for nearly 70% [23]. - The European market grew by 17% year-on-year, with international emerging business growth nearing 30% [23]. Future Outlook - The company aims to maintain revenue above 30 billion yuan in 2025, with an increasing share of international business [25]. - Continuous product upgrades in IVD assembly lines, high-end imaging, and multi-scenario device integration are prioritized [25][26].

Financial Performance - In 2025, the company achieved a revenue of CNY 33.282 billion, a year-on-year decline of 9.38% [2] - Net profit for 2025 was CNY 8.451 billion, down 28.01% year-on-year, with a non-recurring net profit of CNY 8.362 billion, a decrease of 27.28% [2] - Operating cash flow net amount was CNY 10.145 billion, down 18.40% year-on-year [2] - In Q4 2025, revenue was CNY 7.448 billion, a 2.86% increase year-on-year, while net profit decreased by 38.54% to CNY 0.638 billion [2] Shareholder Returns - The company has maintained a consistent dividend policy since its A-share listing in 2018, with total dividends amounting to approximately CNY 37.336 billion by the end of last year [3] - For 2025, the proposed cash dividend distribution is CNY 3.76 billion, with total cash dividends for the year expected to reach CNY 5.310 billion, accounting for 65.27% of the annual net profit [3] International Business Performance - International revenue reached CNY 17.650 billion, a year-on-year increase of 7.40%, accounting for 53% of total revenue [4] - The European market saw a 17% growth in 2025, building on a high growth base from 2024 [4] - Emerging international business segments grew nearly 30% year-on-year [4] Domestic Business Performance - Domestic revenue was CNY 15.632 billion, a decline of 22.97% year-on-year [6] - The domestic medical device industry has faced significant adjustments, with procurement budgets under pressure, leading to a weak recovery phase [7] - The in vitro diagnostics (IVD) sector has entered a contraction phase, with reagent usage and prices declining [7] Product Line Performance - The in vitro diagnostics segment generated CNY 12.241 billion, a decrease of 9.41%, making it the largest revenue contributor at approximately 37% of total revenue [8] - The life information and support segment reported CNY 9.837 billion, down 19.80%, with international revenue accounting for 74% [9] - The medical imaging segment achieved CNY 5.717 billion, a decline of 18.02%, with international revenue at 65% [11] - Emerging business segments generated CNY 5.378 billion, a year-on-year increase of 38.85%, accounting for about 16% of total revenue [12] R&D Investment and New Products - R&D investment for 2025 was CNY 3.929 billion, representing 11.80% of revenue [14] - New product launches included various diagnostic kits and automated systems aimed at enhancing market competitiveness [14][15] Future Outlook - The company aims to deepen its overseas localization and high-end strategic customer penetration, particularly in the European and emerging markets [5] - The domestic business is expected to achieve positive growth in 2026, with a stable growth phase anticipated from 2027 onwards [36] - The IVD business is projected to be a key growth driver, with plans to double market share in the next three years [30] Market Challenges and Strategies - The company faces challenges from high inflation and procurement budget cuts in the domestic market, impacting profitability [40] - Strategies include enhancing product competitiveness and expanding into new markets, particularly in IVD and emerging business segments [31][37]

Important Events - Moore Threads signed a contract worth 660 million yuan for the Moore Threads Quasar Intelligent Computing Cluster [1] - Jingwang Electronics has begun shipping 1.6T optical module PCBs [1] - Oni Electronics signed a strategic cooperation agreement for AI workstations with Muxi Co., Ltd [1] - Jerry Holdings signed a sales contract for gas turbine generator sets worth 2.359 billion yuan [1] - China Merchants Energy ordered 10 VLCC oil tankers at a total price of approximately 8.566 billion yuan [1] - China Shipbuilding (core stock) signed a contract for the construction of 10 very large crude carriers with a domestic well-known shipowner, with a value between 8 billion to 9 billion yuan [1] Investment - Dongpeng Beverage plans to use no more than 15 billion yuan of idle self-owned funds for cash management by 2026 [1] - TCL Technology intends to acquire a 45% stake in Guangzhou Huaxing Semiconductor (core stock) for a transaction price of 9.325 billion yuan [1] Buybacks & Increases - China Eastern Airlines plans to repurchase shares worth 500 million to 1 billion yuan, which will all be canceled to reduce registered capital, with a repurchase price not exceeding 5 yuan per share [1] Performance - Agricultural Bank (core stock) expects double-digit growth in revenue and profit by 2025, with average daily RMB deposits growing at the fastest rate in the industry [1] - Mindray Medical anticipates international business revenue of 17.65 billion yuan by 2025, accounting for 53% of total revenue [1] - Silis expects a record revenue of 165.05 billion yuan in 2025, with R&D investment increasing by 77.4% to 12.51 billion yuan [1] - Jixin Technology forecasts a net profit growth of 343.81% for 2025 [1] - Zhaoyan New Drug expects a net profit of 298 million yuan in 2025, a year-on-year increase of 302% [1] - Birun Technology anticipates a total revenue of 1.03 billion yuan in 2025, a 207% increase from the previous year [1] - Zhongji Xuchuang expects a net profit of 10.8 billion yuan in 2025, a year-on-year increase of 109%, and plans to distribute 10 yuan per 10 shares [1] - Salt Lake Co. anticipates a net profit growth of 81.76% in 2025, achieving revenue of 15.501 billion yuan [1] - CICC expects a net profit growth of 71.93% in 2025, planning to distribute 2.3 yuan per 10 shares [1] - Ninebot Company forecasts a net profit growth of 62.17% in 2025 [1] - Lianqi Technology expects a net profit growth of 58.4% in 2025 [1] - Zhaoyi Innovation anticipates a net profit growth of 49.47% in 2025, planning to distribute 7.5 yuan per 10 shares [1] - Zhongwei Company expects a net profit growth of 30.69% in 2025, planning to convert 10 shares into 4.9 shares and distribute 3.5 yuan [1] - Midea Group anticipates a net profit growth of 14.03% in 2025, planning to distribute 38 yuan per 10 shares and repurchase A-shares worth 6.5 billion to 13 billion yuan [1] - Ganfeng Lithium expects a net profit of 1.613 billion yuan in 2025, turning a profit from a loss [1] Quarterly Performance - Newray Co. expects a year-on-year net profit increase of 474%-604% in the first quarter, with price increases across the entire range of hard alloy and tool products [2] - Huarui Precision anticipates a year-on-year net profit increase of 413%-550% in the first quarter, driven by both volume and price increases [2]

Financial Performance - Total revenue for 2025 was 33.282 billion CNY, a year-on-year decrease of 9.38% [3] - Net profit for 2025 was 8.451 billion CNY, down 28.01% year-on-year [3] - Operating cash flow for 2025 was 10.145 billion CNY, a decline of 18.40% year-on-year [3] - Q4 2025 revenue was 7.448 billion CNY, showing a growth of 2.86% year-on-year [4] - Q4 2025 net profit was 0.638 billion CNY, a decrease of 38.54% year-on-year [4] Shareholder Returns - Cumulative dividends since the 2018 IPO reached approximately 37.336 billion CNY, over 6 times the IPO fundraising amount [5] - The dividend payout ratio for 2025 was 65.27% [5] - Total dividends distributed in 2025 amounted to 5.310 billion CNY [5] Market Performance International Market - International revenue was 17.650 billion CNY, accounting for 53% of total revenue, with a year-on-year growth of 7.40% [6] - The European market saw a growth of approximately 17% [6] - Emerging business sectors grew by around 30% [6] Domestic Market - Domestic revenue was 15.632 billion CNY, representing 47% of total revenue, with a year-on-year decline of 22.97% [7] - Positive growth is expected in the domestic market for 2026 [7] Business Segments - Emerging business revenue was 5.378 billion CNY, with a year-on-year growth of 38.85% [8] - Medical imaging revenue was 9.837 billion CNY, down 18.02% year-on-year [8] - Life information and support business revenue was 5.717 billion CNY, down 19.80% year-on-year [8] Innovation and R&D - R&D accounted for 11.80% of total revenue, totaling 3.929 billion CNY [18] - The company applied for a total of 12,983 patents, with 6,567 granted [18] Strategic Developments - The company aims to enhance its international presence and localize its operations to adapt to market changes [31] - Strategic partnerships are being developed to strengthen its position in the global healthcare market [31]

Group 1: Sustainable Development Strategy - Mindray's sustainable development strategy focuses on six key areas, integrating sustainability into every aspect of its value chain to contribute to a healthier future [1] - The company has received multiple awards in sustainable development for 2025, including recognition from the China Listed Companies Association and Wind ESG ratings [1] Group 2: ESG Ratings and Compliance - Mindray achieved an MSCI ESG rating of AA and a CDP climate change questionnaire score of B [1] - The company maintains a 100% compliance training coverage rate for employees and has zero confirmed corruption incidents or litigation cases [1] Group 3: Research and Development - R&D investment reached CNY 3.929 billion, with 5,212 R&D engineers, accounting for 24.48% of total employees; 66.21% of R&D personnel hold a master's degree or higher [5] - Mindray has filed a total of 12,983 patents, including 9,399 invention patents, and has authorized 6,567 patents, with 3,409 being invention patents [5] Group 4: Quality Management and Green Development - The company has undergone 251 quality management system audits with a 100% pass rate, and all production bases are certified under ISO 9001 or ISO 13485 [9] - Mindray aims to reduce carbon emissions intensity by 25% by 2030 compared to 2021 levels, with a 9.1% reduction target for 2025 [10] Group 5: Employee Development and Diversity - Mindray employs 21,288 staff globally, with 17.28% being foreign employees; 34.80% of the workforce are women, and 26.90% of R&D positions are held by women [15] - The company has a 100% training coverage rate for employee health and safety management [15] Group 6: Community Engagement and Philanthropy - Mindray's initiatives include screening 312 cleft lip and palate patients in Yunnan, providing free surgeries for 189 cases, and raising over CNY 72,000 for Smile Action [17] - The company has committed to training 480,000 people in emergency response by 2025 and has successfully treated 427 cardiac arrest patients using its AED devices [19] Group 7: Future Vision - Mindray aims to drive high-quality development through technological innovation, ecological collaboration, and global expansion to enhance healthcare access [20]